Screening for hepatitis C virus infection in adults

Chou R, Cottrell EB, Wasson N, Rahman B, Guise J-M
Record ID 32013000772
English
Authors' objectives: Many patients with chronic hepatitis C virus (HCV) infection are unaware of their status. Screening could identify patients at earlier stages of disease, when interventions might be effective in improving clinical outcomes or reducing transmission risk. The purpose of this report is to systematically review the evidence on screening for HCV infection in asymptomatic adults without known liver enzyme abnormalities, including pregnant women. This review focuses on research gaps identified in the 2004 United States Preventive Services Task Force (USPSTF) review and new studies published since that review, and it reviews evidence on prenatal HCV screening not included in the 2004 USPSTF review. This report examines both direct evidence on the effects of screening for HCV infection compared to no screening on clinical outcomes, as well as the indirect chain of evidence (diagnosis, workup, and treatment) needed to understand effects of screening on clinical outcomes. Treatments evaluated included immunizations, counseling, and interventions to potentially reduce risk of mother-to-child transmission. To complement this review of screening for HCV, the Agency for Healthcare Research and Quality (AHRQ) commissioned a separate review on effectiveness of antiviral treatments.
Authors' recommendations: Although screening tests can accurately identify adults with chronic HCV infection, targeted screening strategies based on the presence of risk factors miss some patients with HCV infection. As a result, more research is needed to understand the effects of different screening strategies on clinical outcomes. Evidence on effects of knowledge of HCV status and counseling and immunizations on clinical and intermediate outcomes in patients diagnosed with HCV infection remains sparse and more research is needed to understand effective interventions for preventing vertical transmission. A complete assessment of benefits and harms of screening requires consideration of the effectiveness of antiviral regimens, which are the subject of a complementary review.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Hepatitis C
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.